These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Henry SP; Geary RS; Yu R; Levin AA Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363 [TBL] [Abstract][Full Text] [Related]
10. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Crooke RM Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572 [TBL] [Abstract][Full Text] [Related]
11. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Rubenstein M; Tsui P; Guinan P Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790 [TBL] [Abstract][Full Text] [Related]
12. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922 [TBL] [Abstract][Full Text] [Related]
13. Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. Ferrari N; Bergeron D; Tedeschi AL; Mangos MM; Paquet L; Renzi PM; Damha MJ Ann N Y Acad Sci; 2006 Oct; 1082():91-102. PubMed ID: 17145930 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer. Rubenstein M; Anderson KM; Tsui P; Guinan P Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of second generation antisense oligonucleotides. Yu RZ; Grundy JS; Geary RS Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):169-82. PubMed ID: 23231725 [TBL] [Abstract][Full Text] [Related]
17. Antisense drug discovery and development. Yamamoto T; Nakatani M; Narukawa K; Obika S Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846 [TBL] [Abstract][Full Text] [Related]
18. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Dirin M; Winkler J Expert Opin Biol Ther; 2013 Jun; 13(6):875-88. PubMed ID: 23451977 [TBL] [Abstract][Full Text] [Related]
19. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. White PJ; Anastasopoulos F; Pouton CW; Boyd BJ Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730 [TBL] [Abstract][Full Text] [Related]
20. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties. Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]